Overview

MK-5475 in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

Status:
Recruiting
Trial end date:
2022-02-02
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to assess MK-5475 in the PH-COPD population by evaluating the safety, pharmacokinetics (PK), changes in pulmonary vascular resistance (PVR), and changes in pulmonary blood volume (PBV) after administration. The primary study hypothesis is that the MK-5475 results in superior reduction of the mean PVH following 28 days of dosing compared to placebo in participants with PH-COPD.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.